Mallinckrodt plc Ordinary Shares (MNK): Price and Financial Metrics


Mallinckrodt plc Ordinary Shares (MNK): $10.50

-0.20 (-1.87%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MNK Stock Price Chart Interactive Chart >

Price chart for MNK

MNK Price/Volume Stats

Current price $10.50 52-week high $31.00
Prev. close $10.70 52-week low $0.10
Day low $10.45 Volume 15,700
Day high $10.57 Avg. volume 32,029
50-day MA $13.97 Dividend yield N/A
200-day MA $0.00 Market Cap 138.30M

Mallinckrodt plc Ordinary Shares (MNK) Company Bio


Mallinckrodt Public Limited Company is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology, neonatal critical care respiratory therapies, and analgesics and central nervous system drugs. The company was founded in 2013 and is based in Dublin, Ireland.


MNK Latest News Stream


Event/Time News Detail
Loading, please wait...

MNK Latest Social Stream


Loading social stream, please wait...

View Full MNK Social Stream

Latest MNK News From Around the Web

Below are the latest news stories about MALLINCKRODT PLC that investors may wish to consider to help them evaluate MNK as an investment opportunity.

Walmart to Settle Opioid Claims for $3.1 Billion

Litigation over opioid manufacturing and distribution has led to settlements totaling more than $54 billion

Yahoo | November 15, 2022

Mallinckrodt plc Reports Third Quarter 2022 Financial Results and Reaffirms Guidance

Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the third quarter ended September 30, 2022.1

Yahoo | November 8, 2022

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver Meeting

Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that seven scientific abstracts on clinical and health economic outcomes research on treatment with TERLIVAZ® (terlipressin) for adult patients with hepatorenal syndrome (HRS) involving rapid reduction in kidney function,1 an acute and life-threatening condition requiring hospitalization2 will be presented at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver Meeting in Wash

Yahoo | November 3, 2022

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2022 Scientific Meeting

Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that three scientific abstracts on clinical research on treatment with TERLIVAZ® (terlipressin) for adult patients with hepatorenal syndrome (HRS) involving rapid reduction in kidney function,1 will be presented at the American Society of Nephrology (ASN) Kidney Week 2022 Scientific Meeting in Orlando, Florida, from November 3-6. TERLIVAZ is the first and only FDA-approved product indicated to impro

Yahoo | November 1, 2022

Read More 'MNK' Stories Here

MNK Price Returns

1-mo -27.59%
3-mo N/A
6-mo N/A
1-year N/A
3-year 207.92%
5-year -50.82%
YTD N/A
2021 N/A
2020 0.00%
2019 -77.91%
2018 -29.96%
2017 -54.72%

Continue Researching MNK

Want to see what other sources are saying about Mallinckrodt plc's financials and stock price? Try the links below:

Mallinckrodt plc (MNK) Stock Price | Nasdaq
Mallinckrodt plc (MNK) Stock Quote, History and News - Yahoo Finance
Mallinckrodt plc (MNK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6036 seconds.